1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Mitochondrial Diseases in 7 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Mitochondrial Diseases: Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Silibinin administration restored these mitochondrial disorders, as expected for the protection against MPTP injury." | 1.62 | Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus. ( Fu, J; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, W; Liu, X; Mizuno, K; Song, S; Wang, C, 2021) |
| "Gaucher disease is an autosomal recessive disease, caused by a lack or functional deficiency of the lysosomal enzyme, glucocerebrosidase (GCase)." | 1.42 | Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. ( Alvarez-Fischer, D; Andreas, H; Hirsch, EC; Höglinger, GU; Höllerhage, M; Lu, L; Noelker, C; Oertel, WH; Roscher, R; Sturn, A; Vulinovic, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Wang, C | 1 |
| Liu, W | 1 |
| Song, S | 1 |
| Fu, J | 1 |
| Hayashi, T | 1 |
| Mizuno, K | 1 |
| Hattori, S | 1 |
| Fujisaki, H | 1 |
| Ikejima, T | 1 |
| Santos-Alves, E | 1 |
| Marques-Aleixo, I | 1 |
| Coxito, P | 1 |
| Balça, MM | 1 |
| Rizo-Roca, D | 1 |
| Rocha-Rodrigues, S | 1 |
| Martins, S | 1 |
| Torrella, JR | 1 |
| Oliveira, PJ | 1 |
| Moreno, AJ | 1 |
| Magalhães, J | 1 |
| Ascensão, A | 1 |
| Noelker, C | 1 |
| Lu, L | 1 |
| Höllerhage, M | 1 |
| Vulinovic, F | 1 |
| Sturn, A | 1 |
| Roscher, R | 1 |
| Höglinger, GU | 1 |
| Hirsch, EC | 1 |
| Oertel, WH | 1 |
| Alvarez-Fischer, D | 1 |
| Andreas, H | 1 |
| Lagrue, E | 1 |
| Abert, B | 1 |
| Nadal, L | 1 |
| Tabone, L | 1 |
| Bodard, S | 1 |
| Medja, F | 1 |
| Lombes, A | 1 |
| Chalon, S | 1 |
| Castelnau, P | 1 |
| Przedborski, S | 1 |
| Tieu, K | 1 |
| Perier, C | 1 |
| Vila, M | 1 |
| Battaglia, G | 1 |
| Farrace, MG | 1 |
| Mastroberardino, PG | 1 |
| Viti, I | 1 |
| Fimia, GM | 1 |
| Van Beeumen, J | 1 |
| Devreese, B | 1 |
| Melino, G | 1 |
| Molinaro, G | 1 |
| Busceti, CL | 1 |
| Biagioni, F | 1 |
| Nicoletti, F | 1 |
| Piacentini, M | 1 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Kim, J | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Matson, WR | 1 |
| Ryu, H | 1 |
| Ferrante, RJ | 1 |
1 review available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Mitochondrial Diseases
| Article | Year |
|---|---|
MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Apoptosis; Disease Mo | 2004 |
6 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Mitochondrial Diseases
| Article | Year |
|---|---|
Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; alpha-Synuclein; Animals; Apopto | 2021 |
Exercise mitigates diclofenac-induced liver mitochondrial dysfunction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biom | 2014 |
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.
Topics: 1-Deoxynojirimycin; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cells, | 2015 |
MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Basal Ganglia Diseases; Diseas | 2009 |
Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Basal Ganglia Disease | 2007 |
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |